These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 11329847

  • 1. Bayesian cost-effectiveness analysis. An example using the GUSTO trial.
    Fryback DG, Chinnis JO, Ulvila JW.
    Int J Technol Assess Health Care; 2001; 17(1):83-97. PubMed ID: 11329847
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
    Lorenzoni R, Pagano D, Mazzotta G, Rosen SD, Fattore G, De Caterina R, Gensini G.
    Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
    [Abstract] [Full Text] [Related]

  • 4. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction.
    Kalish SC, Gurwitz JH, Krumholz HM, Avorn J.
    J Gen Intern Med; 1995 Jun; 10(6):321-30. PubMed ID: 7562123
    [Abstract] [Full Text] [Related]

  • 5. Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation.
    Boland A, Dundar Y, Bagust A, Haycox A, Hill R, Mujica Mota R, Walley T, Dickson R.
    Health Technol Assess; 2003 Jun; 7(15):1-136. PubMed ID: 12773258
    [No Abstract] [Full Text] [Related]

  • 6. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM, Vijan S, Hayward RA, Griffith JL, Beshansky JR, Selker HP.
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness analysis of thrombolytic treatment for stroke.
    Mar J, Begiristain JM, Arrazola A.
    Cerebrovasc Dis; 2005 Aug; 20(3):193-200. PubMed ID: 16088115
    [Abstract] [Full Text] [Related]

  • 8. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, Barbash G, White H, Simoons ML, Nelson CL.
    N Engl J Med; 1995 May 25; 332(21):1418-24. PubMed ID: 7723799
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Medical decision making in the choice of a thrombolytic agent for acute myocardial infarction. Quebec Acute Coronary Care Working Group.
    Brophy JM, Joseph L, Theroux P.
    Med Decis Making; 1999 May 25; 19(4):411-8. PubMed ID: 10520679
    [Abstract] [Full Text] [Related]

  • 11. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria.
    Coyle D, Buxton MJ, O'Brien BJ.
    Health Econ; 2003 May 25; 12(5):421-7. PubMed ID: 12720259
    [Abstract] [Full Text] [Related]

  • 12. Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs.
    Tsui W, Pierre K, Massel D.
    Can J Cardiol; 2005 Apr 25; 21(5):423-31. PubMed ID: 15861260
    [Abstract] [Full Text] [Related]

  • 13. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase.
    Kent DM, Hayward RA, Griffith JL, Vijan S, Beshansky JR, Califf RM, Selker HP.
    Am J Med; 2002 Aug 01; 113(2):104-11. PubMed ID: 12133748
    [Abstract] [Full Text] [Related]

  • 14. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
    Lorenzoni R, Fattore G, Gensini G.
    G Ital Cardiol; 1997 Jul 01; 27(7):721-6. PubMed ID: 9303862
    [Abstract] [Full Text] [Related]

  • 15. Biases in Individualized Cost-effectiveness Analysis: Influence of Choices in Modeling Short-Term, Trial-Based, Mortality Risk Reduction and Post-Trial Life Expectancy.
    van Klaveren D, Wong JB, Kent DM, Steyerberg EW.
    Med Decis Making; 2017 Oct 01; 37(7):770-778. PubMed ID: 28854143
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction.
    Naylor CD, Bronskill S, Goel V.
    Can J Cardiol; 1993 Oct 01; 9(6):553-8. PubMed ID: 8221354
    [No Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke: experience from Australian stroke center.
    Tan Tanny SP, Busija L, Liew D, Teo S, Davis SM, Yan B.
    Stroke; 2013 Aug 01; 44(8):2269-74. PubMed ID: 23780955
    [Abstract] [Full Text] [Related]

  • 18. Cost and quality of life: thrombolysis and primary angioplasty.
    Goldman L.
    J Am Coll Cardiol; 1995 Jun 01; 25(7 Suppl):38S-41S. PubMed ID: 7775713
    [Abstract] [Full Text] [Related]

  • 19. Emergent decision-making: defining the patient perspective.
    Knudtson ML.
    Can J Cardiol; 2005 Apr 01; 21(5):433-4. PubMed ID: 15861261
    [No Abstract] [Full Text] [Related]

  • 20. Thrombolysis in the developing world: is there a role for streptokinase?
    Butcher K, Shuaib A, Saver J, Donnan G, Davis SM, Norrving B, Wong KS, Abd-Allah F, Bhatia R, Khan A.
    Int J Stroke; 2013 Oct 01; 8(7):560-5. PubMed ID: 23336290
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.